☰
Institutional Grade Valuation

DCFTOOL.APP

Advanced Discounted Cash Flow modeling & real-time watchlist tracking.

Start Valuation

Launch the DCF engine

→

Watchlist

Track portfolio prices

→

Contact Support

Get help & answers

→

Egetis Therapeutics AB (publ) (EGTX) Valuation & Financial Model

Interactive Discounted Cash Flow (DCF) model for Egetis Therapeutics AB (publ) (STO:EGTX), currently being evaluated. In 2025, Egetis Therapeutics AB (publ) generated $62.40 Million in revenue and -$268.60 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.

Valuation Methodology & Recent Performance

The financial model for Egetis Therapeutics AB (publ) is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:

STO:EGTX DCF Model Intrinsic Value 2025 Financials

Advanced Financial Modeling Platform

Welcome to DCFTool.app, an institutional-grade financial analysis suite designed for modern value investors. This platform provides an automated discounted cash flow model paired with a live intrinsic value calculator to streamline your equity research and valuation workflows.

Institutional DCF Engine

Customize terminal growth rate models, utilize multiple calculation variables, or isolate asset liquidation frameworks.

Real-Time Macro Metrics

Integrate a real-time WACC calculator framework or apply localized corporate and foreign withholding tax parameters dynamically.

Valuation Portfolio Tracker

Save calculations to a highly customizable stock valuation watchlist tracker to capture historical performance variance instantly.